Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Expects $27.7M in Net Proceeds from Public Offering

NEW YORK (GenomeWeb News) – Rosetta Genomics said in a regulatory filing on Thursday that it anticipates raising about $27.7 million in a public offering.

In a document filed with the US Securities and Exchange Commission, the company did not price the offering, which it announced last month, but said it is offering 3 million shares. The $27.7 million assumes a public offering price of $10.15 — the last reported sale price of its common share on the Nasdaq on July 24. Net proceeds will increase by about $4.2 million if underwriters exercise an overallotment option.

Aegis Capital is listed as the underwriter in the offering.

Net proceeds will go toward operations and other general corporate purposes, including repayment of loans, working capital, intellectual property protection and enforcement, and R&D.

In June Rosetta netted proceeds of about $6 million from a direct offering.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.